Epidemiology
A rare cartilage sarcoma that can arise in bone or soft tissue, often in young patients. Unlike conventional chondrosarcoma, it usually requires complete systemic staging from the outset.
Basic features
It behaves more aggressively than conventional chondrosarcoma and can present as a soft-tissue mass. The diagnosis is confirmed by the characteristic HEY1::NCOA2 fusion, the test that separates it from conventional chondrosarcoma: a decisive distinction, because the systemic treatment of the two is completely different.
Usual treatment
Unlike conventional chondrosarcoma, it is sensitive to chemotherapy: management combines wide resection with Ewing-type chemotherapy (regimens with an anthracycline and alkylating agents) and, depending on the site, radiotherapy. Before chemotherapy starts it is worth discussing fertility preservation with the team, because some of these treatments can affect it and the options have to be raised beforehand.
Outcomes and prognosis
The prognosis is guarded and worsens over the long term; the risk of metastasis and late recurrence calls for prolonged surveillance, even when the initial tumor is controlled.